The ISHARES Biotech and Russell Small Cap combine as the largest institutional holders of POZN.
The recent share sell off in large cap BIO has been accompanied by selling in ISHARES index fund for BIO, and dragged POZN down with it. Though POZN is only a small fraction of the ISHARES index, the fact is that POZN shares are thinly traded to begin with, so this index selling has had a major drag impact on POZN.
The question investors must ask is whether POZN is representative of the ISHARES basket of biotech holdings.
My answer is no. POZN is now better positioned than any time in its history, and its earnings growth can be of very large proportions indeed. Note that analysts have hiked 2010 numbers to over a 0.50/share profit in recent 2 weeks.
It is $0.54 (EPS for 2010) actually, and without anything from PA. A patnership can provide extra $0.50 EPS on agreement only, and PA, if Pozen go-it-alone may realize much more than $0.50 extra EPS in 2011.